Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia

Journal of Medicinal Chemistry

Volumn 59, Issue 18, 2016, Pages 8189-8206

  Keseru, György M ^a   Erlanson, Daniel A ^b   Ferenczy, György G ^a   Hann, Michael M ^c   Murray, Christopher W ^d   Pickett, Stephen D ^c  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Carmot Therapeutics Inc   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; DRUG; ENDOTHIAPEPSIN; HEAT SHOCK PROTEIN 90; INTEGRASE; LIGAND; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE 14; TRYPSIN; INTEGRASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN KINASE INHIBITOR; TRYPSIN INHIBITOR;

DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; MOLECULAR LIBRARY; MOLECULAR SIZE; NONHUMAN; REVIEW; TECHNOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; PHARMACOLOGY;

ANIMALS; CHECKPOINT KINASE 2; DRUG DESIGN; HIV INTEGRASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES; TRYPSIN INHIBITORS;

EID: 84984690427     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00197     Document Type: Review

References (145)

1. Hann, M. M.; Oprea, T. L. Pursuing the leadlikeness concept in pharmaceutical research Curr. Opin. Chem. Biol. 2004, 8, 255-263 10.1016/j.cbpa.2004.04.003
2. Hall, R. J.; Mortenson, P. N.; Murray, C. W. Efficient exploration of chemical space by fragment-based screening Prog. Biophys. Mol. Biol. 2014, 116, 82-91 10.1016/j.pbiomolbio.2014.09.007
3. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192 10.1038/nchem.217
4. Ferenczy, G. G.; Keseru, G. M. On the enthalpic preference of fragment binding MedChemComm 2016, 7, 332-337 10.1039/C5MD00542F
5. Ferenczy, G. G.; Keseru, G. M. How are fragments optimized? A retrospective analysis of 145 fragment optimizations J. Med. Chem. 2013, 56, 2478-2486 10.1021/jm301851v
6. Hann, M. M.; Keseru, G. M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discovery 2012, 11, 355-365 10.1038/nrd3701
7. Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
8. Edfeldt, F. N.; Folmer, R. H.; Breeze, A. L. Fragment screening to predict druggability (ligandability) and lead discovery success Drug Discovery Today 2011, 16, 284-287 10.1016/j.drudis.2011.02.002
9. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A"Rule of Three" for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877 10.1016/S1359-6446(03)02831-9
10. Jhoti, H.; Williams, G.; Rees, D. C.; Murray, C. W. The 'rule of three' for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discovery 2013, 12, 644-645 10.1038/nrd3926-c1
11. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 2001, 41, 856-864 10.1021/ci000403i
12. Palmer, N.; Peakman, T. M; Norton, D.; Rees, D. C. Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD) Org. Biomol. Chem. 2016, 14, 1599-1610 10.1039/C5OB02461G
13. Davis, B. J.; Erlanson, D. A. Learning from our mistakes: the 'unknown knowns' in fragment screening Bioorg. Med. Chem. Lett. 2013, 23, 2844-2852 10.1016/j.bmcl.2013.03.028
14. Practical Fragments Blog; http://practicalfragments.blogspot.hu/2014/01/poll-results-affiliation-fragment.html (accessed Jan 20, 2016).
15. Optibrium Home Page; http://www.optibrium.com/downloads/Swain-Fragments.pdf (accessed Jan 20, 2016).
16. Siegal, G.; Eiso, A. B.; Schultz, J. Integration of fragment screening and library design Drug Discovery Today 2007, 12, 1032-1039 10.1016/j.drudis.2007.08.005
17. Devine, S. M.; Mulcair, M. D.; Debono, C. O.; Leung, E. W. W.; Nissink, J. W. M.; Lim, S. S.; Chandrashekaran, I. R.; Vazirani, M.; Mohanty, B.; Simpson, J. S.; Baell, J. B.; Scammells, P. J.; Norton, R. S.; Scanlon, M. J. Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold J. Med. Chem. 2015, 58, 1205-1214 10.1021/jm501402x
18. Bauman, J. D.; Harrison, J. J. E. K.; Arnold, E. Rapid experimental SAD phasing and hot-spot identification with halogenated fragments IUCrJ 2016, 3, 51-60 10.1107/S2052252515021259
19. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S.; Fong, D.; Zhu, Y. L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3041-3046 10.1073/pnas.0711741105
20. Shipe, W. D.; Sharik, S. S.; Barrow, J. C.; McGaughey, G. B.; Theberge, C. R.; Uslaner, J. M.; Yan, Y.; Renger, J. J.; Smith, S. M.; Coleman, P. J.; Cox, C. D. Discovery and optimization of a series of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors through fragment screening, structure-based design, and parallel synthesis J. Med. Chem. 2015, 58, 7888-7894 10.1021/acs.jmedchem.5b00983
21. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740 10.1021/jm901137j
22. Baell, J. B.; Walters, M. A. Chemistry: Chemical con artists foil drug discovery Nature. 2014, 513, 481-483 10.1038/513481a
23. Irwin, J. J.; Duan, D.; Torosyan, H.; Doak, A. K.; Ziebart, K. T.; Sterling, T.; Tumanian, G.; Shoichet, B. K. An aggregation advisor for ligand discovery J. Med. Chem. 2015, 58, 7076-7087 10.1021/acs.jmedchem.5b01105
24. Leach, A. R.; Hann, M. M.; Burrows, J. N.; Griffen, E. J. Fragment screening: an introduction Mol. BioSyst. 2006, 2, 429-446 10.1039/b610069b
25. Giannetti, A. M. From experimental design to validated hits: a comprehensive walk-through of fragment lead identification using surface plasmon resonance. In Methods in Enzymology, Lawrence, C. K., Ed. Academic Press: New York, 2011; Vol. 493, pp 169-218.
26. Bamborough, P.; Brown, M. J.; Christopher, J. A.; Chung, C.-w.; Mellor, G. W. Selectivity of kinase inhibitor fragments J. Med. Chem. 2011, 54, 5131-5143 10.1021/jm200349b
27. Schuffenhauer, A.; Ruedisser, S.; Marzinzik, A. L.; Jahnke, W.; Blommers, M.; Selzer, P.; Jacoby, E. Library design for fragment based screening Curr. Top. Med. Chem. 2005, 5, 751-762 10.2174/1568026054637700
28. Lau, W. F.; Withka, J. M.; Hepworth, D.; Magee, T. V.; Du, Y. J.; Bakken, G. A.; Miller, M. D.; Hendsch, Z. S.; Thanabal, V.; Kolodziej, S. A.; Xing, L.; Hu, Q.; Narasimhan, L. S.; Love, R.; Charlton, M. E.; Hughes, S.; van Hoorn, W. P.; Mills, J. E. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics J. Comput.-Aided Mol. Des. 2011, 25, 621-36 10.1007/s10822-011-9434-0
29. Chen, I. J.; Hubbard, R. E. Lessons for fragment library design: analysis of output from multiple screening campaigns J. Comput.-Aided Mol. Des. 2009, 23, 603-620 10.1007/s10822-009-9280-5
30. Wielens, J.; Headey, S. J.; Rhodes, D. I.; Mulder, R. J.; Dolezal, O.; Deadman, J. J.; Newman, J.; Chalmers, D. K.; Parker, M. W.; Peat, T. S.; Scanlon, M. J. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J. Biomol. Screening 2013, 18, 147-159 10.1177/1087057112465979
31. Silva-Santisteban, M. C.; Westwood, I. M.; Boxall, K.; Brown, N.; Peacock, S.; McAndrew, C.; Barrie, E.; Richards, M.; Mirza, A.; Oliver, A. W.; Burke, R.; Hoelder, S.; Jones, K.; Aherne, G. W.; Blagg, J.; Collins, I.; Garrett, M. D.; van Montfort, R. L. Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2 PLoS One 2013, 8, e65689 10.1371/journal.pone.0065689
32. Pollack, S. J.; Beyer, K. S.; Lock, C.; Müller, I.; Sheppard, D.; Lipkin, M.; Hardick, D.; Blurton, P.; Leonard, P. M.; Hubbard, P. A.; Todd, D.; Richardson, C. M.; Ahrens, T.; Baader, M.; Hafenbradl, D. O.; Hilyard, K.; Bürli, R. W. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights J. Comput.-Aided Mol. Des. 2011, 25, 677-687 10.1007/s10822-011-9454-9
33. Boettcher, A.; Ruedisser, S.; Erbel, P.; Vinzenz, D.; Schiering, N.; Hassiepen, U.; Rigollier, P.; Mayr, L. M.; Woelcke, J. Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12 J. Biomol. Screening 2010, 15, 1029-1041 10.1177/1087057110380455
34. Meiby, E.; Simmonite, H.; le Strat, L.; Davis, B.; Matassova, N.; Moore, J. D.; Mrosek, M.; Murray, J.; Hubbard, R. E.; Ohlson, S. Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90 Anal. Chem. 2013, 85, 6756-6766 10.1021/ac400715t
35. Schiebel, J.; Radeva, N.; Köster, H.; Metz, A.; Krotzky, T.; Kuhnert, M.; Diederich, W. E.; Heine, A.; Neumann, L.; Atmanene, C.; Roecklin, D.; Vivat-Hannah, V.; Renaud, J. P.; Meinecke, R.; Schlinck, N.; Sitte, A.; Popp, F.; Zeeb, M.; Klebe, G. One question, multiple answers: biochemical and biophysical screening methods retrieve deviating fragment hit lists ChemMedChem 2015, 10, 1511-21 10.1002/cmdc.201500267
36. Kutchukian, P. S.; Wassermann, A. M.; Lindvall, M. K.; Wright, S. K.; Ottl, J.; Jacob, J.; Scheufler, C.; Marzinzik, A.; Brooijmans, N.; Glick, M. Large scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologies J. Biomol. Screening 2015, 20, 588-96 10.1177/1087057114565080
37. Wall, I. D.; Hann, M. M.; Leach, A. R.; Pickett, S. D. Current status and future direction of fragment-based drug discovery: a computational chemistry perspective. In Fragment-Based Drug Discovery; Howard, S.; Abell, C., Eds.; RSC: London, 2015; pp 73-100.
38. Chessari, G.; Buck, I. M.; Day, J. E.; Day, P. J.; Iqbal, A.; Johnson, C. N.; Lewis, E. J.; Martins, V.; Miller, D.; Reader, M.; Rees, D. C.; Rich, S. J.; Tamanini, E.; Vitorino, M.; Ward, G. A.; Williams, P. A.; Williams, G.; Wilsher, N. E.; Woolford, A. J. Fragment-based drug discovery targeting inhibitor of apoptosis proteins: discovery of a non-alanine lead series with dual activity against cIAP1 and XIAP J. Med. Chem. 2015, 58, 6574-6588 10.1021/acs.jmedchem.5b00706
39. Bortolato, A.; Tehan, B. G.; Bodnarchuk, M. S.; Essex, J. W.; Mason, J. S. Water network perturbation in ligand binding: adenosine A2A antagonists as a case study J. Chem. Inf. Model. 2013, 53, 1700-1713 10.1021/ci4001458
40. Nilar, S. H.; Ma, N. L.; Keller, T. H. The importance of molecular complexity in the design of screening libraries J. Comput.-Aided Mol. Des. 2013, 27, 783-792 10.1007/s10822-013-9683-1
41. Leach, A. R.; Hann, M. M. Molecular complexity and fragment-based drug discovery: ten years on Curr. Opin. Chem. Biol. 2011, 15, 489-496 10.1016/j.cbpa.2011.05.008
42. Hann, M. M.; Leach, A. R. Coping with complexity in molecular design. In De Novo Molecular Design; Schneider, G., Ed.; Wiley-VCH Verlag GmbH & Co: Weinheim, Germany, 2014; pp 57-77.
43. Ferenczy, G. G.; Keseru, G. M. Thermodynamics of fragment binding J. Chem. Inf. Model. 2012, 52, 1039-1045 10.1021/ci200608b
44. Mortenson, P. N.; Murray, C. W. Assessing the lipophilicity of fragments and early hits J. Comput.-Aided Mol. Des. 2011, 25, 663-667 10.1007/s10822-011-9435-z
45. Verdonk, M. L.; Rees, D. C. Group efficiency: a guideline for hits-to-leads chemistry ChemMedChem 2008, 3, 1179-1180 10.1002/cmdc.200800132
46. Hung, A. W.; Silvestre, H. L.; Wen, S.; George, G. P.; Boland, J.; Blundell, T. L.; Ciulli, A.; Abell, C. Optimization of inhibitors of Mycobacterium tuberculosis pantothenate synthetase based on group efficiency analysis ChemMedChem 2016, 11, 38-42 10.1002/cmdc.201500414
47. Young, R. J. Physical properties in drug design. In Tactics in Contemporary Drug Design; Meanwell, N. A., Ed.; Springer: Berlin, Gemany, 2015; pp 1-68.
48. Mattos, C.; Bellamacina, C. R.; Peisach, E.; Pereira, A.; Vitkup, D.; Petsko, G. A.; Ringe, D. Multiple solvent crystal structures: probing binding sites, plasticity and hydration J. Mol. Biol. 2006, 357, 1471-1482 10.1016/j.jmb.2006.01.039
49. Hall, D. R.; Kozakov, D.; Vajda, S. Analysis of protein binding sites by computational solvent mapping Methods Mol. Biol. 2012, 819, 13-27 10.1007/978-1-61779-465-0-2
50. Kozakov, D.; Hall, D.; Napoleon, R. L.; Yueh, C.; Whitty, A.; Vajda, S. New frontiers in druggability J. Med. Chem. 2015, 58, 9063-9088 10.1021/acs.jmedchem.5b00586
51. Practical Fragments Blog; http://practicalfragments.blogspot.hu/2013/06/poll-results-how-small-are-your.html (accessed Jan 20, 2016).
52. Van Molle, I.; Thomann, A.; Buckley, D. L.; So, E. C.; Lang, S.; Crews, C. M.; Ciulli, A. Dissecting fragment-based lead discovery at the von Hippel-Lindau Protein: hypoxia inducible factor 1α protein-protein interface Chem. Biol. 2012, 19, 1300-1312 10.1016/j.chembiol.2012.08.015
53. Fry, D. C.; Wartchow, C.; Graves, B.; Janson, C.; Lukacs, C.; Kammlott, U.; Belunis, C.; Palme, S.; Klein, C.; Vu, B. Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor ACS Med. Chem. Lett. 2013, 4, 660-665 10.1021/ml400062c
54. Lange, G.; Lesuisse, D.; Deprez, P.; Schoot, B.; Loenze, P.; Bénard, D.; Marquette, J.-P.; Broto, P.; Sarubbi, E.; Mandine, E. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of pp60Src are identical to those for high affinity binding of full length inhibitors J. Med. Chem. 2003, 46, 5184-5195 10.1021/jm020970s
55. Andersen, O. A.; Nathubhai, A.; Dixon, M. J.; Eggleston, I. M.; van Aalten, D. M. Structure-based dissection of the natural product cyclopentapeptide Chitinase inhibitor argifin Chem. Biol. 2008, 15, 295-301 10.1016/j.chembiol.2008.02.015
56. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J.-M.; Krimm, I. Fragment-based deconstruction of Bcl-XL inhibitors J. Med. Chem. 2010, 53, 2577-2588 10.1021/jm100009z
57. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery Nat. Chem. Biol. 2006, 2, 720-723 10.1038/nchembio831
58. Satoh, M.; Saburi, H.; Tanaka, T.; Matsuura, Y.; Naitow, H.; Shimozono, R.; Yamamoto, N.; Inoue, H.; Nakamura, N.; Yoshizawa, Y.; Aoki, T.; Tanimura, R.; Kunishima, N. Multiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulation FEBS Open Bio 2015, 5, 557-70 10.1016/j.fob.2015.06.011
59. Barelier, S.; Cummings, J. A.; Rauwerdink, A. M.; Hitchcock, D. S.; Farelli, J. D.; Almo, S. C.; Raushel, F. M.; Allen, K. N.; Shoichet, B. K. Substrate deconstruction and the nonadditivity of enzyme recognition J. Am. Chem. Soc. 2014, 136, 7374-7382 10.1021/ja501354q
60. Brandt, P.; Geitmann, M.; Danielson, U. H. Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments J. Med. Chem. 2011, 54, 709-718 10.1021/jm101052g
61. Edink, E.; Rucktooa, P.; Retra, K.; Akdemir, A.; Nahar, T.; Zuiderveld, O.; van Elk, R.; Janssen, E.; van Nierop, P.; van Muijlwijk-Koezen, J.; Smit, A. B.; Sixma, T. K.; Leurs, R.; de Esch, I. J. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis J. Am. Chem. Soc. 2011, 133, 5363-5371 10.1021/ja110571r
62. Bauman, J. D.; Patel, D.; Baker, S. F.; Vijayan, R. S.; Xiang, A.; Parhi, A. K.; Martínez-Sobrido, L.; Lavoie, E. J.; Das, K.; Arnold, E. Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors ACS Chem. Biol. 2013, 8, 2501-2508 10.1021/cb400400j
63. Chen, Y.; Shoichet, B. K. Molecular docking and ligand specificity in fragment-based inhibitor discovery Nat. Chem. Biol. 2009, 5, 358-364 10.1038/nchembio.155
64. Orita, M.; Ohno, K.; Warizaya, M.; Amano, Y.; Niimi, T. Lead generation and examples: opinion regarding how to follow up hits Methods Enzymol. 2011, 493, 383-419 10.1016/B978-0-12-381274-2.00015-7
65. Kozakov, D.; Hall, D. R.; Jehle, S.; Luo, L.; Ochiana, S. O.; Jones, E. V.; Pollastri, M.; Allen, K. N.; Whitty, A.; Vajda, S. Ligand deconstruction: Why some fragment binding positions are conserved and others are not Proc. Natl. Acad. Sci. U. S. A. 2015, 112, E2585-E2594 10.1073/pnas.1501567112
66. Ludlow, R. F.; Verdonk, M. L.; Saini, H. K.; Tickle, I. J.; Jhoti, H. Detection of secondary binding sites in proteins using fragment screening Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 15910-15915 10.1073/pnas.1518946112
67. Vass, M.; ágai-Csongor, é.; Horti, F.; Keseru, G. M. Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors ACS Med. Chem. Lett. 2014, 5, 1010-1014 10.1021/ml500201u
68. Christopher, J. A.; Aves, S. J.; Bennett, K. A.; Doré, A. S.; Errey, J. C.; Jazayeri, A.; Marshall, F. H.; Okrasa, K.; Serrano-Vega, M. J.; Tehan, B. G.; Wiggin, G. R.; Congreve, M. Fragment and structure-based drug discovery for a class C GPCR: Discovery of the mGlu5 negative allosteric modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile) J. Med. Chem. 2015, 58, 6653-6664 10.1021/acs.jmedchem.5b00892
69. Protein Data Bank; http://www.rcsb.org/pdb/home/home.do (accesssed on 22 January, 2016).
70. Murray, C. W.; Rees, D. C. Opportunity knocks: organic chemistry for fragment-based drug discovery (FBDD) Angew. Chem., Int. Ed. 2016, 55, 488-492 10.1002/anie.201506783
71. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces J. Mol. Biol. 1998, 280, 1-9 10.1006/jmbi.1998.1843
72. Fraser, C. M.; Fernández, A.; Scott, L. R. Dehydron analysis: quantifying the effect of hydrophobic groups on the strength and stability of hydrogen bonds Adv. Exp. Med. Biol. 2010, 680, 473-479 10.1007/978-1-4419-5913-3-53
73. Young, T.; Abel, R.; Kim, B.; Berne, B. J.; Friesner, R. A. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 808-813 10.1073/pnas.0610202104
74. Muley, L.; Baum, B.; Smolinski, M.; Freindorf, M.; Heine, A.; Klebe, G.; Hangauer, D. G. Enhancement of hydrophobic interactions and hydrogen bond strength by cooperativity: synthesis, modeling, and molecular dynamics simulations of a congeneric series of thrombin inhibitors J. Med. Chem. 2010, 53, 2126-2135 10.1021/jm9016416
75. Barelier, S.; Krimm, I. Ligand specificity, privileged substructures and protein druggability from fragment-based screening Curr. Opin. Chem. Biol. 2011, 15, 469-474 10.1016/j.cbpa.2011.02.020
76. Hann, M. M. Molecular obesity, potency and other addictions in drug discovery MedChemComm 2011, 2, 349-355 10.1039/c1md00017a
77. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136 10.1016/j.sbi.2006.01.013
78. Nair, P. C.; Malde, A. K.; Drinkwater, N.; Mark, A. E. Missing fragments: detecting cooperative binding in fragment-based drug design ACS Med. Chem. Lett. 2012, 3, 322-326 10.1021/ml300015u
79. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery Nat. Rev. Drug Discovery 2004, 3, 660-672 10.1038/nrd1467
80. Borsi, V.; Calderone, V.; Fragai, M.; Luchinat, C.; Sarti, N. Entropic contribution to the linking coefficient in fragment based drug design: a case study J. Med. Chem. 2010, 53, 4285-4289 10.1021/jm901723z
81. Nazaré, M.; Matter, H.; Will, D. W.; Wagner, M.; Urmann, M.; Czech, J.; Schreuder, H.; Bauer, A.; Ritter, K.; Wehner, V. Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetic of fragment linking in protein-ligand complexes Angew. Chem., Int. Ed. 2012, 51, 905-911 10.1002/anie.201107091
82. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins J. Comput.-Aided Mol. Des. 2002, 16, 741-753 10.1023/A:1022446720849
83. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756 10.1021/jm901241e
84. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020 10.1016/j.drudis.2009.07.014
85. Kenny, P. W.; Montanari, C. A. Inflation of correlation in the pursuit of drug-likeness J. Comput.-Aided Mol. Des. 2013, 27, 1-13 10.1007/s10822-012-9631-5
86. Morley, A. D.; Pugliese, A.; Birchall, K.; Bower, J.; Brennan, P.; Brown, N.; Chapman, T.; Drysdale, M.; Gilbert, I. H.; Hoelder, S.; Jordan, A.; Ley, S. V.; Merritt, A.; Miller, D.; Swarbrick, M. E.; Wyatt, P. G. Fragment-based hit identification: thinking in 3D Drug Discovery Today 2013, 18, 1221-1227 10.1016/j.drudis.2013.07.011
87. Pascolutti, M.; Campitelli, M.; Nguyen, B.; Pham, N.; Gorse, A. D.; Quinn, R. J. Capturing Nature's diversity PLoS One 2015, 10, e0120942 10.1371/journal.pone.0120942
88. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds J. Med. Chem. 2006, 49, 2969-2978 10.1021/jm0512185
89. Olsson, T. S.; Williams, M. A.; Pitt, W. R.; Ladbury, J. E. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design J. Mol. Biol. 2008, 384, 1002-1017 10.1016/j.jmb.2008.09.073
90. Kozakov, D.; Grove, L. E.; Hall, D. R.; Bohnuud, T.; Mottarella, S. E.; Luo, L.; Xia, B.; Beglov, D.; Vajda, S. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins Nat. Protoc. 2015, 10, 733-755 10.1038/nprot.2015.043
91. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525 10.1021/jm049131r
92. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009 10.1038/nature06526
93. Andrews, S. P.; Brown, G. A.; Christopher, J. A. Structure-based and fragment-based GPCR drug discovery ChemMedChem 2014, 9, 256-275 10.1002/cmdc.201300382
94. Akritopoulou-Zanze, I.; Hajduk, P. J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors Drug Discovery Today 2009, 14, 291-297 10.1016/j.drudis.2008.12.002
95. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010, 467, 596-599 10.1038/nature09454
96. Addie, M.; Ballard, P.; Buttar, D.; Crafter, C.; Currie, G.; Davies, B. R.; Debreczeni, J.; Dry, H.; Dudley, P.; Greenwood, R.; Johnson, P. D.; Kettle, J. G.; Lane, C.; Lamont, G.; Leach, A.; Luke, R. W.; Morris, J.; Ogilvie, D.; Page, K.; Pass, M.; Pearson, S.; Ruston, L. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases J. Med. Chem. 2013, 56, 2059-2073 10.1021/jm301762v
97. Mérour, J. Y.; Buron, F.; Plé, K.; Bonnet, P.; Routier, S. The azaindole framework in the design of kinase inhibitors Molecules 2014, 19, 19935-19979 10.3390/molecules191219935
98. Karpov, A. S.; Amiri, P.; Bellamacina, C.; Bellance, M. H.; Breitenstein, W.; Daniel, D.; Denay, R.; Fabbro, D.; Fernandez, C.; Galuba, I.; Guerro-Lagasse, S.; Gutmann, S.; Hinh, L.; Jahnke, W.; Klopp, J.; Lai, A.; Lindvall, M. K.; Ma, S.; Möbitz, H.; Pecchi, S.; Rummel, G.; Shoemaker, K.; Trappe, J.; Voliva, C.; Cowan-Jacob, S. W.; Marzinzik, A. L. Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor ACS Med. Chem. Lett. 2015, 6, 776-781 10.1021/acsmedchemlett.5b00102
99. Allen, C. E.; Welford, A. J.; Matthews, T. P.; Caldwell, J. J.; Collins, I. Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments MedChemComm 2014, 5, 180-185 10.1039/C3MD00308F
100. Bauman, J. D.; Patel, D.; Dharia, C.; Fromer, M. W.; Ahmed, S.; Frenkel, Y.; Vijayan, R. S.; Eck, J. T.; Ho, W. C.; Das, K.; Shatkin, A. J.; Arnold, E. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening J. Med. Chem. 2013, 56, 2738-2746 10.1021/jm301271j
101. Palmieri, L.; Rastelli, G. αC helix displacement as a general approach for allosteric modulation of protein kinases Drug Discovery Today 2013, 18, 407-414 10.1016/j.drudis.2012.11.009
102. American Society of Hematology; https://ash.confex.com/ash/2014/webprogram/Paper76344.html (accessed Jan 20, 2016).
103. Murray, J.; Giannetti, A. M.; Steffek, M.; Gibbons, P.; Hearn, B. R.; Cohen, F.; Tam, C.; Pozniak, C.; Bravo, B.; Lewcock, J.; Jaishankar, P.; Ly, C. Q.; Zhao, X.; Tang, Y.; Chugha, P.; Arkin, M. R.; Flygare, J.; Renslo, A. R. Tailoring small molecules for an allosteric site on procaspase-6 ChemMedChem 2014, 9, 73-77 10.1002/cmdc.201300424
104. Saalau-Bethell, S. M.; Woodhead, A. J.; Chessari, G.; Carr, M. G.; Coyle, J.; Graham, B.; Hiscock, S. D.; Murray, C. W.; Pathuri, P.; Rich, S. J.; Richardson, C. J.; Williams, P. A.; Jhoti, H. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function Nat. Chem. Biol. 2012, 8, 920-925 10.1038/nchembio.1081
105. Magee, T. V. Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening Bioorg. Med. Chem. Lett. 2015, 25, 2461-2468 10.1016/j.bmcl.2015.04.089
106. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins J. Med. Chem. 2008, 51, 6902-6915 10.1021/jm800669s
107. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C. M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat. Med. 2013, 19, 202-208 10.1038/nm.3048
108. Burke, J. P.; Bian, Z.; Shaw, S.; Zhao, B.; Goodwin, C. M.; Belmar, J.; Browning, C. F.; Vigil, D.; Friberg, A.; Camper, D. V.; Rossanese, O. W.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design J. Med. Chem. 2015, 58, 3794-3805 10.1021/jm501984f
109. Petros, A. M.; Swann, S. L.; Song, D.; Swinger, K.; Park, C.; Zhang, H.; Wendt, M. D.; Kunzer, A. R.; Souers, A. J.; Sun, C. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein Bioorg. Med. Chem. Lett. 2014, 24, 1484-1488 10.1016/j.bmcl.2014.02.010
110. Scott, D. E.; Coyne, A. G.; Venkitaraman, A.; Blundell, T. L.; Abell, C.; Hyvönen, M. Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases ChemMedChem 2015, 10, 296-303 10.1002/cmdc.201402428
111. Maurer, T.; Garrenton, L. S.; Oh, A.; Pitts, K.; Anderson, D. J.; Skelton, N. J.; Fauber, B. P.; Pan, B.; Malek, S.; Stokoe, D.; Ludlam, M. J.; Bowman, K. K.; Wu, J.; Giannetti, A. M.; Starovasnik, M. A.; Mellman, I.; Jackson, P. K.; Rudolph, J.; Wang, W.; Fang, G. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 5299-5304 10.1073/pnas.1116510109
112. Sun, Q.; Burke, J. P.; Phan, J.; Burns, M. C.; Olejniczak, E. T.; Waterson, A. G.; Lee, T.; Rossanese, O. W.; Fesik, S. W. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation Angew. Chem., Int. Ed. 2012, 51, 6140-6143 10.1002/anie.201201358
113. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand discovery Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9367-72 10.1073/pnas.97.17.9367
114. Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: fragment-based drug discovery Annu. Rev. Biophys. Biomol. Struct. 2004, 33, 199-223 10.1146/annurev.biophys.33.110502.140409
115. Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Nature 2013, 503, 548-551 10.1038/nature12796
116. Kathman, S. G.; Xu, Z.; Statsyuk, A. V. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases J. Med. Chem. 2014, 57, 4969-4974 10.1021/jm500345q
117. Miller, R. M.; Paavilainen, V. O.; Krishnan, S.; Serafimova, I. M.; Taunton, J. Electrophilic fragment-based design of reversible covalent kinase inhibitors J. Am. Chem. Soc. 2013, 135, 5298-5301 10.1021/ja401221b
118. London, N.; Miller, R. M.; Krishnan, S.; Uchida, K.; Irwin, J. J.; Eidam, O.; Gibold, L.; Cimermančič, P.; Bonnet, R.; Shoichet, B. K.; Taunton, J. Covalent docking of large libraries for the discovery of chemical probes Nat. Chem. Biol. 2014, 10, 1066-1072 10.1038/nchembio.1666
119. Blomberg, N.; Cosgrove, D. A.; Kenny, P. W.; Kolmodin, K. Design of compound libraries for fragment screening J. Comput.-Aided Mol. Des. 2009, 23, 513-525 10.1007/s10822-009-9264-5
120. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Comput. Sci. 1998, 38, 511-522 10.1021/ci970429i
121. Cox, O. B.; Krojer, T.; Collins, P.; Monteiro, O.; Talon, R.; Bradley, A.; Fedorov, O.; Amin, J.; Marsden, B. D.; Spencer, J.; von Delft, F.; Brennan, P. E. A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain Chem. Sci. 2016, 7, 2322-2330 10.1039/C5SC03115J
122. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery Chem. Biol. 1999, 6, 755-769 10.1016/S1074-5521(00)80022-8
123. Pihan, E.; Colliandre, L.; Guichou, J. F.; Douguet, D. E-Drugs3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design Bioinformatics 2012, 28, 1540-1541 10.1093/bioinformatics/bts186
124. Hung, A. W.; Ramek, A.; Wang, Y.; Kaya, T.; Wilson, J. A.; Clemons, P. A.; Young, D. W. Route to three-dimensional fragments using diversity-oriented synthesis Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 6799-6804 10.1073/pnas.1015271108
125. Feher, M.; Schmidt, J. M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry J. Chem. Inf. Comput. Sci. 2003, 43, 218-227 10.1021/ci0200467
126. Ertl, P.; Roggo, S.; Schuffenhauer, A. Natural product-likeness score and its application for prioritization of compound libraries J. Chem. Inf. Model. 2008, 48, 68-74 10.1021/ci700286x
127. Over, B.; Wetzel, S.; Grütter, C.; Nakai, Y.; Renner, S.; Rauh, D.; Waldmann, H. Natural-product-derived fragments for fragment-based ligand discovery Nat. Chem. 2013, 5, 21-28 10.1038/nchem.1506
128. Vu, H.; Roullier, C.; Campitelli, M.; Trenholme, K. R.; Gardiner, D. L.; Andrews, K. T.; Skinner-Adams, T.; Crowther, G. J.; Van Voorhis, W. C.; Quinn, R. J. Plasmodium gametocyte inhibition identified from a natural-product-based fragment library ACS Chem. Biol. 2013, 8, 2654-2659 10.1021/cb400582b
129. Cambridge Medchem Consulting; http://www.cambridgemedchemconsulting.com/resources/hit-identification/fragment-collections.html (accessed 22 January, 2016).
130. Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology J. Med. Chem. 2013, 56, 1363-1388 10.1021/jm3012068
131. Cambridge MedChem Consulting; http://www.cambridgemedchemconsulting.com/resources/hit-identification/fragment-collection-profiles.html (accessed Apr 4, 2016).
132. Nadin, A.; Hattotuwagama, C.; Churcher, I. Lead-oriented synthesis: A new opportunity for synthetic chemistry Angew. Chem., Int. Ed. 2012, 51, 1114-1122 10.1002/anie.201105840
133. Cernak, T.; Dykstra, K. D.; Tyagarajan, S.; Vachal, P.; Krska, S. W. The medicinal chemist's toolbox for late stage functionalization of drug-like molecules Chem. Soc. Rev. 2016, 45, 546-576 10.1039/C5CS00628G
134. Lengyel, L. C.; Sipos, G.; Sipocz, T.; Vago, T.; Dorman, G.; Gerencser, J.; Makara, G.; Darvas, F. Synthesis of condensed heterocycles by the Gould-Jacobs reaction in a novel three-mode pyrolysis reactor Org. Process Res. Dev. 2015, 19, 399-409 10.1021/op500354z
135. Personal communication from Justin Bower, 4 April 2016.
136. Practical Fragments Blog; http://practicalfragments.blogspot.com/2014/10/caveat-emptor.html (accessed Jan 20, 2016).
137. Doak, B. C.; Morton, C. J.; Simpson, J. S.; Scanlon, M. J. Design and evaluation of the performance of an NMR screening fragment library Aust. J. Chem. 2013, 66, 1465-1472 10.1071/CH13280
138. Davies, D. R.; Mamat, B.; Magnusson, O. T.; Christensen, J.; Haraldsson, M. H.; Mishra, R.; Pease, B.; Hansen, E.; Singh, J.; Zembower, D.; Kim, H.; Kiselyov, A. S.; Burgin, A. B.; Gurney, M. E.; Stewart, L. J. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography J. Med. Chem. 2009, 52, 4694-4715 10.1021/jm900259h
139. Procházková, E.; Jansa, P.; Březinová, A.; Cechová, L.; Mertlíková-Kaiserová, H.; Holý, A.; Dračínský, M. Compound instability in dimethyl sulfoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening Bioorg. Med. Chem. Lett. 2012, 22, 6405-6409 10.1016/j.bmcl.2012.08.065
140. McElhinny, C. J., Jr.; Lewin, A. H.; Mascarella, S. W.; Runyon, S.; Brieaddy, L.; Carroll, F. I. Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies Bioorg. Med. Chem. Lett. 2012, 22, 6661-6664 10.1016/j.bmcl.2012.08.109
141. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davis, B.; Drysdale, M.; Dymock, B.; Finch, H.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R. E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets J. Chem. Inf. Comput. Sci. 2004, 44, 2157-2166 10.1021/ci049806z
142. Kozikowski, B. A.; Burt, T. M.; Tirey, D. A.; Williams, L. E.; Kuzmak, B. R.; Stanton, D. T.; Morand, K. L.; Nelson, S. L. The effect of room-temperature storage on the stability of compounds in DMSO J. Biomol. Screening 2003, 8, 205-209 10.1177/1087057103252617
143. Oldenburg, K.; Pooler, D.; Scudder, K.; Lipinski, C.; Kelly, M. High throughput sonication: evaluation for compound solubilization Comb. Chem. High Throughput Screening 2005, 8, 499-512 10.2174/1386207054867364
144. Practical Fragments Blog; http://practicalfragments.blogspot.com/2014/02/poll-results-how-do-you-store-your.html (accessed Jan 20, 2016).
145. Practical Fragments Blog; http://practicalfragments.blogspot.com/2015/01/fragments-in-clinic-2015-edition.html (accessed Jan 20, 2016).